Graphite Bio (Graphite Bio) Debt-to-EBITDA : -0.01 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Graphite Bio Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Graphite Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.29 Mil. Graphite Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.08 Mil. Graphite Bio's annualized EBITDA for the quarter that ended in Dec. 2023 was $-57.84 Mil. Graphite Bio's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Graphite Bio's Debt-to-EBITDA or its related term are showing as below:

GRPH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -76.03 Med: -0.12 Max: -0.01
Current: -0.01

During the past 5 years, the highest Debt-to-EBITDA Ratio of Graphite Bio was -0.01. The lowest was -76.03. And the median was -0.12.

GRPH's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs GRPH: -0.01

Graphite Bio Debt-to-EBITDA Historical Data

The historical data trend for Graphite Bio's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Graphite Bio Debt-to-EBITDA Chart

Graphite Bio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-76.03

-0.19

-0.06

-0.01

Graphite Bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial												-0.06	-0.05	-0.67	-1.03	-0.01

Competitive Comparison of Graphite Bio's Debt-to-EBITDA

For the Biotechnology subindustry, Graphite Bio's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Graphite Bio's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Graphite Bio's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Graphite Bio's Debt-to-EBITDA falls into.

Graphite Bio Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Graphite Bio's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.285	+	0.077)	/	-70.703
	=	-0.01

Graphite Bio's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.285	+	0.077)	/	-57.84
	=	-0.01

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Graphite Bio (NAS:GRPH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Graphite Bio Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Graphite Bio's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Graphite Bio (Graphite Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Graphite Bio Inc (NAS:GRPH) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskins Way, Suite 210, South San Francisco, CA, USA, 94080

Website

https://www.graphitebio.com

Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.

Executives

Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Samsara Biocapital, L.p.	10 percent owner	628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Phil Gutry	officer: CHIEF BUSINESS OFFICER	400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Alethia Young	officer: Chief Financial Officer	C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Versant Ventures Vi Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Matthew Porteus	director	C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Katherine V Stultz	officer: CHIEF OPERATING OFFICER	C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Abraham Bassan	director	C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
L.p. 436,	10 percent owner	628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Versant Vantage Ii Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Rizzuto Carlo	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Smital Shah	director	C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080